Alterity Therapeutics
Alterity Therapeutics Limited focuses on developing therapies to treat neurodegenerative diseases associated with aging, like Alzheimer's and Parkinson's disease. The company leverages a novel drug development platform aimed at targeting misfolded proteins. Positioned as a pioneer in this field, Alterity aims to address significant unmet needs in the neurosciences market.
Short position
Alterity Therapeutics (ASX:ATH) has 0.02% of its shares on issue reported as short positions as of 5 Oct 2026, or about 45,003 shares. Over the past 30 days that figure has fallen 0.09 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.18% in January 2024. ATH is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Alterity Therapeutics (ATH) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0vs $0 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$23.4Mvs −$12.1M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.11vs −$0.095 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- −55.0%
- ROA
- −50.8%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $37.3M
- Net debt / EBITDA
- n/a
- Current ratio
- 14.5×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $77.2M
- P/E
- n/a
- P/B
- 1.8×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and Derived: trailing 12 months at year end, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating income | −$25.1M | −$12.5M | −$19.6M | −$14.7M |
| EBITDA | −$25.0M | −$12.3M | −$19.5M | −$14.6M |
| EBIT | −$25.1M | −$12.5M | −$19.6M | −$14.7M |
| Pretax income | −$23.3M | −$12.1M | −$19.1M | −$13.7M |
| Tax | $113.5K | $68.1K | $46.1K | $104.5K |
| NPAT | −$23.4M | −$12.1M | −$19.1M | −$13.8M |
| Net interest income | $1.7M | $446.3K | $268.4K | $16.4K |
| EPS basic | −$0.11 | −$0.095 | −$0.26 | −$0.28 |
| EPS diluted | −$0.11 | −$0.095 | −$0.26 | −$0.28 |
| Shares | 217.5M | 182.5M | 104.9M | 48.8M |
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Half Yearly Report and AccountsHalf Year Results28 Feb 2025via asx_announcements
Showing 10 of 97 reports